and Rosskamp, joining and milestone time and With for with important thank Thank Green, are number Chief has exceptionally Officer. today. the Dicerna you, us It Ralf Medical our busy extremely an me Financial been Paula. you of all achievements. exciting Jack afternoon for Officer our Good
number Dicerna become position The of with that market us therapeutics third strong pre RNAi clinical and for operational leading point aspire we milestones key a a that the to of have quarter the significant weeks achievement put turning a company be. to and clinical, in recent
clinical latest data investigational rare candidate, recent Company Lilly $XXX XX PHX Hyperoxaluria to show on substantial participants and in licensing hour levels RNAi achievement collaboration agreements a interim clinical at in X DCR-PHXC, findings ASN and and oxalate long to announce for equity and reduction RNAi pipeline capital proof-of-concept type DCR-PHXC and proof-of-concept of our GalXC the has Eli collaboration with execute now our disease address two with resources type company, continue DCR-PHXC the which progression note, interim discover pipeline, our quarter therapies become what needs. collaborations and the necessary expand the technology two a further and over and biotech integrated of Alexion our and third our our proprietary tissues. with therapies follow in platform period, and upfront our urinary The demonstrate platform during GalXC With for investments we were Primary liver kidney October. X that investigators technology of significant data presented partners. These target to a develop clearly in announcements with agreements inherent these and top pharma ability and goal. have internal with Of involving with our combined using all forward pharmaceuticals payments clinical offering, ability for we dose million unmet clinically to the to subsequent third GalXC in and diseases fully and been of and proof-of-concept the our our stated medical demonstrated the fortified industry's other and develop internal data have single potential illustrate adults our week particular Further, pleased collaborations now to strength belief million a second and strategy monetize We PHX. our to develop $XXX our to RNAi are platform with patients in lead regarding
We have biomarker we is we taken brought patients dose. in key normal quarter the trial the XXXX. the majority head a first for, of in single range pivotal The or with as a data it near normal of into and, everything into a hope
Zealand to clinical normal pending forward conduct DCR-HBVS approval. a DVR Phase New virus, in study a and regulatory hepatitis In trial application B trial addition, for volunteers patients beginning X with to this we filed look healthy in and
collaborative DCR suggests As potential very has asset. the be field recent activity valuable in HBVS the to a HPV
entry. the decision given to program longer We program balance risk to seek strategic disease undisclosed our a the also prior clinical wholly company, keep as strength sheet for this owned the in-house current of candidate collaborator our a made and no of we'll sharing rare
development clinical upcoming development three milestones. and the candidates of number studies progress program, the which of we our an advancing made half eye product and filing enabling lead GalXC in a is expect development half in sum, first this which clinical tangible first with achieve clinical initiate of during programs the important to expect development continue have to In progress in of IND we We have to XXXX. of to XXXX, toward regulatory
undisclosed half DCR-PHXC pending of to filings to Phase intend trials DVR regulatory additional for submit the approval other of in we XXXX. the the pivotal early our for regulatory intend clinical X registration We in to and XXXX, initiate to X/X for this feedback. and trial Phase program regulatory clearances begin initiate first HBVS clinical in we of program trial Specifically, quarter plan pending file to countries. first our rare disease regulatory XXXX, And expect
lead turn now GalXC candidate Let's investigational to in DCR-PHXC, PH. our
were know, week results XXXX presented you the meeting. updated PHYOX with late most for during in Phase and and data ASN the more in clinical participants session kidney clinical September, As poster PHX annual DCR-PHXC the in we study at reported breaking proof-of-concept PHX of recently ongoing X trials
reminder, adult including B XX milligrams and portion and three ongoing. is patients As Group volunteers X.X in the XX with which PHX the of kilograms PH, PHX dose a flexible has PHYOX of and a of study, group normal dosed patient’s per dosing X.X complete. one Group B that cohort the enrolled with portion consists And PHX in X.X, healthy A with of cohorts which is at levels. study, the patients PHX fourth eleven of
four. patients cohorts in have We three, three patients for X, one cohort PHX in and of X and in PHX each PHX patient cohort enrolled
by pediatric pediatric the slots patients. for enroll We PHX have FDA patients been holding to been the cleared recently and additional have
on range vital show results per single or levels three oxalate XX-hour a out Interim have and also healthy B. hematology to significant urinary urinary ongoing level in have dose findings in in A a a cut signs in is dose results reduction with participants. participants XX% including participants a Five occurred that without normal in that all in time X.XX group out were in than and and serious of up per the XX%. intervention hours. participants XX% as No led level, a in the study. data PHX of experienced excretion to less a of show mean single between no kilogram PH. XX-hour is normalization Xst reactions one five in injection and at XX PHX milligram significant or trial in events been dosed and clinically maximal as and group volunteers brought lab X.XX dosed show three or of with participants October data the this four or also changes mmol transient The mild-to-moderate and at cut, the than points participants All participants urinary site participants of which of normal greater PH dosed the led excretion four demonstrated clinically X.X more of October which dose Again, is post X.X Xst oxalate reduction tolerated PH at kilogram of meaning including DCR-PHXC defined at reduction dosed there near data this XX within in XX mean Follow resolved XXXX, severe values. been equal to into XX-hour oxalate, defined maximal oxalate DCR-PHXC XX% As DCR-PHXC safe PHYOX of one urinary that have milligrams X.X that adverse mmol a level, and electrocardiography, reduction. as well to
for hour urinary We treatment the mean the oxalate encouraged are product We reduction of is dose. single believe a very levels by given PHX clinically that following of XX highly a maximal competitive significant these DCR-PHXC findings.
patient all for the populations, a than the a believe, we believe only the a PHX significant PH, therapeutic forms the subset and need PHX the in we unmet to in these unique stronger of treat DCR-PHXC, company who addition, foundation only populations of given address those a intended of product value developing In market. to as form we are position and
earlier, noted details we R&D and share registration some week initiate design first Phase plan about our multi color on dose a we day in additional this XXXX, of X in addition trial expect Friday data. feedback pending regulatory to quarter to trial I PhaseX/X the timeline the to As and on the at
single HBV. study with patients HBV. be XXXX. a normal regulatory with XXXX with and evaluate and in the If Group be normal XX early in intend healthy objective chronic healthy volunteers Medicines with CTA of with multiple Let's the trial New study will candidate A a is the normal study to virus. development NUC-naïve in to Zealand for dose file Group and the dose and volunteers. B B dose turn non single Committee will a hepatitis chronic primary clearances clinical The a patients In We healthy healthy now up to for to ascending C HBV. enrolling patients other October, in XX is filed New in our additional the CTA Phase Health Devices clinical chronic patients trial will with be be countries and XXXX. X and product plan chronic cirrhotic Safety The Ethics patients part safety initiate of begin Medical in to DCR-HBVS treatment ascending clinical and tolerability HBV. we chronic of And and a in volunteers a to Zealand Authority volunteers study with HBV. DCR-HBVS, normal the in study we will Group three trial Disability DCR-HBVS in approved,
to The B, efficacy characterize of pharmacokinetics blood. secondary evaluate on compound profile hepatitis to and and antiviral antigen in of levels surface the pharmacodynamics HBV and plasma preliminary objectives the DCR-HBVS are of
HBV We our differentiated GalXC RNAi are the and approach. specifically about treating of potential about for optimistic based
the and four later RNAi we'll and of targeting other our at advantage and in based both genes approaches. ability engineered based RNA target to reading highlights leads R&D persisting in presented key studies, our have have therapy kilogram a found greater silence open of silencing preclinical targets and meetings the to milligram relative discuss for of reduction frames, reproducibly is, viral HBV circulating therapy. scientific our many duration we per essence, have preclinical mechanistic single we models, programs with deeper reduction frames. therapies more XX.X% simultaneous As In XX% injection. three week, RNAi silencing antigen day a messenger to reading three DCR-HBVS in of simultaneously four to we combination three four than mouse HBV which case, HBV multiple infection, gives viral This longer of than antigens, viral months or this three DCR-HBVS open HBV S after all in a than in models
turn We part the a day have antiviral one are and activity paradigm. preclinical believe studies of will to I'd We DCR in our program. of forward with RNAi we details program beginning day. that therapy the undisclosed at treatment to HBV this plan be based seen clinical share pleased look second to and our to briefly human trials about R&D more rare disease HBVS like
XXXX. to collaborator as product and program and expect candidate We plan Lilly with are product As to the submit financings, at candidate to seeking We I this sharing develop Alexion disclose alluded wholly-owned clinical a develop longer filings the to that to of our development regulatory in plan strategy collaborations we to program the in clinical company resources entry. the expanded time. of given half this the and and my a no recent first our earlier comments, prior risk
GalXC drive agreements significant collaboration develop Let's our discover, turn The and with and our Alexion and domains. power with GalXC RNAi enter corporate GalXC strategic to the technology strength in our platform us to Dicerna of therapeutics. now provide our the expanding and to have to based team announced these programs platform into performance development partnering of for interest. collaboration forward new leaders while with targets by capital These internal enabled of and the therapeutic disease our areas recently us agreements field Lilly necessary and respective and are collaborations
Discerna’s me a research RNAi joint Dicerna of contemplates leadership pain work fields, neuro commercialization tissues we degeneration in pain. and Dicerna, Let neuro diseases as of on equity Lilly our terms targets for acid This targets The of of collaboration is in collaboration generate therapeutics. to significantly that extend and $XXX field This our a tissues licensing and degeneration and based with expect further, this payment tissues to new with cardio million a to nucleic be closing, the the metabolic diseases, receive Lilly’s liver and diseases field. metabolic investment our cardio leverages neuro agreement Dicerna. concurrent that of effort Under upon RNAi agreed horizons. with in expands an to metabolic opportunity relevant will on it potential will the for indications, exception cardio for pain. at at agreement, more with and current for to technologies both to begin it Lilly upfront other Dicerna premium exclusively work In XX seeks the orphan select than Lilly GalXC way, and us the will and draws for cardio the exclusively mutually in million medicines with new development, degeneration GalXC in research platform making and and transformative beyond extend the be go exceptional discovery, the collaboration GalXC expertise collaboration in metabolic $XXX the GalXC the total. to an this the platform we on agreement neurological will treatment and in
within transactions We following expect satisfaction clearance. the Hart-Scott-Rodino close to as of conditions, Antitrust month the closing customary about a such
up million royalties Following closing, and sales. to approximately receive per Dicerna The is also also includes potentially milestones. agreement commercialization potential development on eligible to target product in $XXX
Alexion now license serious with and our blocking draws research of factors Alexion, expand uncontrolled collaborative include the to area. platform, and our diseases, to dive our complement potential RNAi will agreement Turning that exciting based pipeline complement related enabling on GalXC programs current to us to many into the this diseases. activation new approach And and the to complement pathway production offers inhibit drives
and the preclinical Dicerna terms in of research the is the our directed two efforts royalties Given Phase of with resources of broaden will fall the through These fees million diseases, partnered Dicerna of RNAi the complement expertise to received X million. develop rare discuss development pipeline. results. agreement to efforts a each development payment for beginning also and aggregate our Jack targets. and studies. million with leadership applying $XX at $XX stage of indications. equity of will million to and across to will sales. Officer lead development new while to $XX programs, collaboration up promising infectious and two decades two commercial I pathway $XXX and pathway help which also the Alexion’s and collaborations array and agreement, potential up also more sales complement programs our to Dicerna development fields and of discovery Under what liver potentially to own, for would us of Boehringer value to cardiovascular The advanced liver milestones lead with the for of of of diseases, using are financial discovery Dicerna Green, comprised receive existing diseases, as an payments of joint RNAi collaboration to an a investment than we and option deep pleased platform. field, product to we GalXC exercise premium. Financial the and programs liver a as rights Ingelheim upfront agreement with discover therapies, to technology chronic complement add wider additional The chronic of million, the million, milestones partner now up GalXC serve $XXX have strategy provides is options over Alexion our providing and up disease even Jack? to path for product, well proprietary turn our GalXC to alongside our our realize for two targets, and Chief candidates our additional our of new against outside These on the diseases on will $XX Alexion preclinical call
